

Please fill out this page only if you live outside Quebec.

INFORMATION

The prescription drug that is the object of your request is part of our patient support program. Designed to help you better manage your medical condition, this program provides you with many benefits such as access to professional support from a team of pharmacists. For more information, see the *Prior Authorization Drugs and the Patient Support Program* brochure, available at www.desjardinslifeinsurance.com/PAD.

If your contract includes the program, you may be required to participate.

A healthcare professional from the provider selected by Desjardins Insurance will contact you to let you know the status of your request, to explain how the program works and to direct you to a preferred pharmacy. That professional may also contact your attending physician to get any missing information. The information obtained as a result of this prior authorization request will be sent to the third party and used to process your request. This is why your signature is required.

IMPORTANT

As part of the patient support program, you will be reimbursed for your specialty drug only if you purchase it through the preferred pharmacy network.

CONSENT TO DISCLOSE TO A THIRD PARTY

For the sole purpose of the patient support program, I authorize Desjardins Insurance to disclose to the third party personal information about me, especially my medical information, that is needed for the program. I understand that the third party may share this information with my doctors, pharmacists and other healthcare professionals as part of this program.

This consent also applies to the disclosure of personal information concerning my dependents, insofar as this request involves them.

Last name and first name of the member (PLEASE PRINT)

Contract No.

Certificate No.

Email address of the member

Signature of the member

Date

Last name and first name of the parent or legal guardian (if necessary)

Signature of the parent or legal guardian (if necessary)

Date

This consent is an integral part of the attached Prior Authorization Request form.



PRIOR AUTHORIZATION REQUEST

AVSOLA (INFLIXIMAB)

REMICADE (INFLIXIMAB)

PLEASE READ THE INSTRUCTIONS ON THE LAST PAGE OF THIS FORM.

A PATIENT IDENTIFICATION – To be completed by the member.

Patient's last and first name		Relationship with member <input type="checkbox"/> Member <input type="checkbox"/> Spouse <input type="checkbox"/> Dependent child		Patient's date of birth YYYY MM DD	
Member's last and first name			Contract No.		Certificate No.
No., street, apt.			City		Province Postal code
Telephone Nos – Home:		Office:		Extension:	
Email:					

Since the response to this request includes confidential information, please indicate how you would like to be informed of the decision:
 By mail (The response to your request will be sent to the address indicated in this section.) By fax:

Coordination of benefits: If the patient has coverage under a private insurance plan or is enrolled in a provincial drug insurance plan, please submit the request to this plan first. Then send us a copy of the decision notice and this form filled out by the physician, so we can analyze the request.

PRIVATE PLAN

Does the patient have drug coverage under a private insurance plan?
 Yes – Please provide a copy of the notice of approval or refusal. → Copy attached to this form.
 Specify: Name of the insurer: _____ Contract No.: _____ Certificate No.: _____
 No

PROVINCIAL PLAN

Has a request for reimbursement been submitted under your provincial plan?
 Yes – Please provide a copy of the notice of approval or refusal. → Copy attached to this form.
 No – Please explain: _____

PATIENT SUPPORT PROGRAM

Is the patient enrolled in a patient support program? Yes No
 If so – Program name: _____
 Contact person: _____ Telephone No.: _____ Extension: _____

B1 DECLARATION AND AUTHORIZATION FOR THE COLLECTION AND COMMUNICATION OF PERSONAL INFORMATION

All the information I have provided on the claim form is accurate and complete. I authorize Desjardins Financial Security Life Assurance Company, hereinafter Desjardins Insurance, strictly for the purposes of managing my file and settling this claim to: (a) collect from any person or legal entity, or from any public or parapublic organization, only the information deemed necessary to manage my file. The non-exhaustive list of sources from which information may be collected includes healthcare professionals or facilities, and insurance companies; (b) communicate to the said persons or organizations only the personal information about me that is deemed necessary for the purposes of my file; (c) when necessary use the personal information it may have about me in existing files that are now closed. This authorization is also valid for the collection, use and communication of personal information concerning my dependents, insofar as applicable to the claim. A photocopy of this authorization is as valid as the original.

➤ Signature of member: _____ Date: _____
 Last name and first name of parent/legal guardian (if applicable): _____
 Signature of patient or parent/legal guardian (if applicable): _____ Date: _____

B2 CONSENT TO THE COMMUNICATION OF PERSONAL INFORMATION TO A THIRD PARTY

To help us process your claim more efficiently, do you authorize Desjardins Insurance to inform the patient support program and the attending physician or the attending physician's medical team of the reasons for the decision on your prior authorization request?

Yes No

➤ Signature of member: _____ Date: _____
 Last name and first name of parent/legal guardian (if applicable): _____
 Signature of patient or parent/legal guardian (if applicable): _____ Date: _____

C ATTENDING PHYSICIAN SECTION – To be completed by the attending physician.

Physician's last and first name (PLEASE PRINT)		License No.		Specialty	
No., street, suite		City		Province Postal code	
Telephone No.:			Fax No.:		

➤ Signature of physician: _____ Date: _____

Drug name	Formulation	Strength	Dosage	Patient's weight	Scheduled duration of treatment
-----------	-------------	----------	--------	------------------	---------------------------------

Where is the drug administered? Home Physician's office Private clinic Hospital – Inpatient Hospital – Outpatient
 Other (please specify): _____

- Make sure to fill out all sections so we can process the request faster. If any information is missing, we will send the form back to the member.
- In order to consider any diagnosis not mentioned on this form, we need supporting documents (clinical practice guidelines, clinical studies, etc.) that justify the drug's use in the given context.

Requests for treatment with REMICADE will only be considered in exceptional cases, since biosimilar drugs are available on the market. If the patient's situation doesn't allow them to transition to a biosimilar version of REMICADE, indicate the reason below:

- Pregnant patient – Due date: _____ YYYY-MM-DD
- Pediatric patient
- Patient for whom treatment with at least 2 other biologic drugs has failed

Please indicate the biologic drugs that were tried: _____

- Other – Please provide sufficiently documented medical justification.

Diagnosis

- Systemic juvenile idiopathic arthritis
 - Polyarticular juvenile idiopathic arthritis
 - Psoriatic arthritis of the rheumatoid type
 - Psoriatic arthritis other than the rheumatoid type
 - Rheumatoid arthritis
 - Ankylosing spondylitis
 - Crohn's disease
 - Fistulising Crohn's disease
 - Ulcerative colitis
 - Psoriasis
- Other therapeutic indication(s) – Please specify: _____

Information relating to polyarticular or systemic juvenile idiopathic arthritis

Number of joints with active synovitis: _____

Childhood Health Assessment Questionnaire (CHAQ) score: _____

Please provide at least one of the following pieces of information: C-reactive protein value: _____ mg/L

Erythrocyte sedimentation rate value: _____ mm/hr

Information relating to rheumatoid arthritis or psoriatic arthritis

Number of joints with active synovitis: _____

Please provide at least one of the following pieces of information:

Presence of a positive rheumatoid factor: Yes No C-reactive protein value: _____ mg/L

Presence of radiological erosions: Yes No Erythrocyte sedimentation rate value: _____ mm/hr

Health Assessment Questionnaire (HAQ) result: _____

Information relating to ankylosing spondylitis

BASDAI test result: _____ Degree of functional impairment according to the BASFI (scale of 0 to 10): _____

(BASDAI = Bath Ankylosing Spondylitis Disease Activity Index) (BASFI = Bath Ankylosing Spondylitis Functional Index)

Information relating to Crohn's disease – Harvey Bradshaw Index (HBI) score:

Information relating to ulcerative colitis

Mayo score: _____ Mayo endoscopic subscore: _____ Mayo rectal bleeding subscore: _____

Information relating to psoriasis

Presence of significant patches: Face Hands Feet Genital region

Psoriasis Area Severity Index (PASI) result: _____

Dermatology Life Quality Index (DLQI) Evaluation Questionnaire result: _____

PRIOR MEDICATION OR TREATMENT

Has the patient ever used medication or received treatment for this medical condition? Yes No

If not, please explain: _____

If so, please list any medication already used or any treatment already received for this medical condition:

MEDICATION OR TREATMENT NAME	OUTCOME	TREATMENT PERIOD
Name: _____	<input type="checkbox"/> Inefficiency <input type="checkbox"/> Intolerance <input type="checkbox"/> Contraindication	From: _____ YYYY MM DD
Dose: _____	Specify: _____	To: _____ YYYY MM DD
Name: _____	<input type="checkbox"/> Inefficiency <input type="checkbox"/> Intolerance <input type="checkbox"/> Contraindication	From: _____ YYYY MM DD
Dose: _____	Specify: _____	To: _____ YYYY MM DD
Name: _____	<input type="checkbox"/> Inefficiency <input type="checkbox"/> Intolerance <input type="checkbox"/> Contraindication	From: _____ YYYY MM DD
Dose: _____	Specify: _____	To: _____ YYYY MM DD

C ATTENDING PHYSICIAN SECTION – Continued

PRESCRIPTION RENEWAL

Please provide objective data that shows a satisfactory clinical or biological response: _____

D INSTRUCTIONS – HOW TO COMPLETE AND RETURN THIS FORM

1. Complete sections A and B.
2. Ask your physician to complete section C. The member is responsible for assuming any costs incurred to complete this form or to obtain additional information.
3. To obtain a reimbursement once the drug has been approved, please use your payment card at the pharmacy or submit your original receipts by mail. Eligible drugs must be dispensed by a pharmacist or a physician, if there is no pharmacist.
4. Send form:

	by fax: Desjardins Insurance	by mail: Desjardins Insurance
	Group Insurance, Health Claims,	Group Insurance, Health Claims
	418-838-2134 or 1-877-838-2134 (toll-free)	C. P. 3950, Lévis (Québec) G6V 8C6

Under its prior authorization program, Desjardins Insurance authorizes the reimbursement of certain drugs that meet criteria that are based, in particular, on clinical practice guidelines and recommendations issued by health technology assessment organizations. The drug will be eligible for reimbursement if it meets the insurer’s criteria, if it’s not administered in a hospital and if it’s not eligible under a government program. If the information on your form is complete, your request will normally be processed within 5 business days.

When the request form is received, it will be assessed in the strictest confidence. In some situations, additional diagnostic or clinical information may be required.

If the treatment continues beyond the authorized period, you will be asked to submit a new request form and provide information that justifies the extension of treatment. If you have a payment card, your pharmacist will be advised that the authorization period is coming to an end. The insurance must be in force and the patient still covered on the date expenses are incurred. This prior authorization is subject to change if, at the time expenses are incurred, the contract has been modified.

When Desjardins Insurance declines a prior authorization request, it is because we need to uphold conditions set out in the contract. It does not mean we are questioning the physician’s opinion. If you have any questions, please contact our Customer Contact Centre at the number indicated on page 1 of this form.